Recruiting studies: Double Expressor Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06736613 Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Ly
Phase 2 · 2 location(s) · University of California, Davis · NCT05600686 Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06891157 Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
Phase 2 · 1 location(s) · Ou Bai, MD/PHD · NCT07493148 Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
Phase 1/Phase 2 · 8 location(s) · National Cancer Institute (NCI) · NCT07069699 RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT06674096 Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
Phase 2 · 1 location(s) · Rong Tao · NCT07507318

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.